A New Generation of Drug Therapies Requires New Business Strategies

promises to change the nature of competition in the pharmaceuticals industry. ATMs include engineered cell therapies that reprogram cells to fight disease, gene therapies that involve replacing or editing dysfunctional genes, and nucleic acid therapies that promote or shut down production of a protein.

The life sciences industry is undergoing a fundamental evolution in how drugs are discovered, developed, and manufactured. The industry is shifting from traditional drug research and development techniques used for small molecules and antibodies to, a category that encompasses engineered cell therapies that reprogram cells to fight disease, gene therapies that involve replacing or editing dysfunctional genes, and nucleic acid therapies that promote or shut down production of a protein .

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

A New Generation of Drug Therapies Requires New Business StrategiesThe shift toward advanced therapeutic modalities will require life sciences companies to rethink strategy, investments, and risk management.
ソース: HarvardBiz - 🏆 310. / 63 続きを読む »

A New Generation of Drug Therapies Requires New Business StrategiesThe shift toward advanced therapeutic modalities will require life sciences companies to rethink strategy, investments, and risk management.
ソース: HarvardBiz - 🏆 310. / 63 続きを読む »